X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FDC LTD. SHASUN PHARMA/
FDC LTD.
 
P/E (TTM) x 123.9 24.3 510.8% View Chart
P/BV x 8.5 5.1 168.7% View Chart
Dividend Yield % 0.2 0.9 24.9%  

Financials

 SHASUN PHARMA   FDC LTD.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FDC LTD.
Mar-14
SHASUN PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs94144 65.6%   
Low Rs4679 57.7%   
Sales per share (Unadj.) Rs214.247.6 450.3%  
Earnings per share (Unadj.) Rs5.37.6 70.1%  
Cash flow per share (Unadj.) Rs15.89.0 175.6%  
Dividends per share (Unadj.) Rs1.002.25 44.4%  
Dividend yield (eoy) %1.42.0 70.7%  
Book value per share (Unadj.) Rs53.347.5 112.2%  
Shares outstanding (eoy) m56.62177.83 31.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.32.3 14.0%   
Avg P/E ratio x13.114.6 89.6%  
P/CF ratio (eoy) x4.412.3 35.8%  
Price / Book Value ratio x1.32.3 56.0%  
Dividend payout %18.729.6 63.4%   
Avg Mkt Cap Rs m3,95819,784 20.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1641,221 177.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,1278,459 143.4%  
Other income Rs m229394 58.3%   
Total revenues Rs m12,3568,852 139.6%   
Gross profit Rs m1,0092,070 48.7%  
Depreciation Rs m594249 238.3%   
Interest Rs m41531 1,338.6%   
Profit before tax Rs m2302,184 10.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73606 -12.0%   
Profit after tax Rs m3021,353 22.3%  
Gross profit margin %8.324.5 34.0%  
Effective tax rate %-31.727.7 -114.2%   
Net profit margin %2.516.0 15.6%  
BALANCE SHEET DATA
Current assets Rs m6,8844,355 158.1%   
Current liabilities Rs m8,4561,792 471.9%   
Net working cap to sales %-13.030.3 -42.8%  
Current ratio x0.82.4 33.5%  
Inventory Days Days6244 138.6%  
Debtors Days Days10825 436.0%  
Net fixed assets Rs m4,9703,025 164.3%   
Share capital Rs m113179 63.4%   
"Free" reserves Rs m2,8758,243 34.9%   
Net worth Rs m3,0208,453 35.7%   
Long term debt Rs m1,81711 16,985.0%   
Total assets Rs m13,34710,557 126.4%  
Interest coverage x1.671.4 2.2%   
Debt to equity ratio x0.60 47,538.1%  
Sales to assets ratio x0.90.8 113.4%   
Return on assets %5.413.1 41.0%  
Return on equity %10.016.0 62.5%  
Return on capital %13.323.5 56.7%  
Exports to sales %46.413.3 348.3%   
Imports to sales %14.23.3 426.1%   
Exports (fob) Rs m5,6221,126 499.4%   
Imports (cif) Rs m1,728283 610.9%   
Fx inflow Rs m5,8431,146 509.8%   
Fx outflow Rs m2,173355 611.6%   
Net fx Rs m3,669791 464.0%   
CASH FLOW
From Operations Rs m3981,485 26.8%  
From Investments Rs m-1,635-620 263.9%  
From Financial Activity Rs m1,309-753 -173.9%  
Net Cashflow Rs m71113 63.1%  

Share Holding

Indian Promoters % 39.2 68.9 56.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.7 76.6%  
FIIs % 17.6 7.5 234.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 19.0 208.4%  
Shareholders   20,750 23,730 87.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  AJANTA PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS